Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial

Somayyeh Firouzi, Hazreen Abdul Majid, Amin Ismail, Nor Azmi Kamaruddin, Mohd Yusof Barakatun-Nisak

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Aim: Evidence of a possible connection between gut microbiota and several physiological processes linked to type 2 diabetes is increasing. However, the effect of multi-strain probiotics in people with type 2 diabetes remains unclear. This study investigated the effect of multi-strain microbial cell preparation—also refers to multi-strain probiotics—on glycemic control and other diabetes-related outcomes in people with type 2 diabetes. Design: A randomized, double-blind, parallel-group, controlled clinical trial. Setting: Diabetes clinic of a teaching hospital in Kuala Lumpur, Malaysia. Participants: A total of 136 participants with type 2 diabetes, aged 30–70 years, were recruited and randomly assigned to receive either probiotics (n = 68) or placebo (n = 68) for 12 weeks. Outcomes: Primary outcomes were glycemic control-related parameters, and secondary outcomes were anthropomorphic variables, lipid profile, blood pressure and high-sensitivity C-reactive protein. The Lactobacillus and Bifidobacterium quantities were measured before and after intervention as an indicator of successful passage of the supplement through gastrointestinal tract. Statistical analysis: Intention-to-treat (ITT) analysis was performed on all participants, while per-protocol (PP) analysis was performed on those participants who had successfully completed the trial with good compliance rate. Results: With respect to primary outcomes, glycated hemoglobin decreased by 0.14 % in the probiotics and increased by 0.02 % in the placebo group in PP analysis (p <0.05, small effect size of 0.050), while these changes were not significant in ITT analysis. Fasting insulin increased by 1.8 µU/mL in placebo group and decreased by 2.9 µU/mL in probiotics group in PP analysis. These changes were significant between groups at both analyses (p <0.05, medium effect size of 0.062 in PP analysis and small effect size of 0.033 in ITT analysis). Secondary outcomes did not change significantly. Probiotics successfully passed through the gastrointestinal tract. Conclusion: Probiotics modestly improved HbA1c and fasting insulin in people with type 2 diabetes.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalEuropean Journal of Nutrition
DOIs
Publication statusAccepted/In press - 17 Mar 2016

Fingerprint

Probiotics
Type 2 Diabetes Mellitus
Randomized Controlled Trials
Intention to Treat Analysis
Placebos
Gastrointestinal Tract
Fasting
Insulin
Physiological Phenomena
Bifidobacterium
Malaysia
Controlled Clinical Trials
Glycosylated Hemoglobin A
Lactobacillus
Teaching Hospitals
C-Reactive Protein
Hypertension
Lipids

Keywords

  • Blood pressure
  • Glycated hemoglobin
  • Glycemic control
  • High-sensitivity C-reactive protein
  • Homeostasis model assessment-estimated insulin resistance
  • Lipid profile
  • Probiotics
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes : a randomized controlled trial. / Firouzi, Somayyeh; Majid, Hazreen Abdul; Ismail, Amin; Kamaruddin, Nor Azmi; Barakatun-Nisak, Mohd Yusof.

In: European Journal of Nutrition, 17.03.2016, p. 1-16.

Research output: Contribution to journalArticle

@article{e74b958cc9b34abaaf71acde2e998bc9,
title = "Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial",
abstract = "Aim: Evidence of a possible connection between gut microbiota and several physiological processes linked to type 2 diabetes is increasing. However, the effect of multi-strain probiotics in people with type 2 diabetes remains unclear. This study investigated the effect of multi-strain microbial cell preparation—also refers to multi-strain probiotics—on glycemic control and other diabetes-related outcomes in people with type 2 diabetes. Design: A randomized, double-blind, parallel-group, controlled clinical trial. Setting: Diabetes clinic of a teaching hospital in Kuala Lumpur, Malaysia. Participants: A total of 136 participants with type 2 diabetes, aged 30–70 years, were recruited and randomly assigned to receive either probiotics (n = 68) or placebo (n = 68) for 12 weeks. Outcomes: Primary outcomes were glycemic control-related parameters, and secondary outcomes were anthropomorphic variables, lipid profile, blood pressure and high-sensitivity C-reactive protein. The Lactobacillus and Bifidobacterium quantities were measured before and after intervention as an indicator of successful passage of the supplement through gastrointestinal tract. Statistical analysis: Intention-to-treat (ITT) analysis was performed on all participants, while per-protocol (PP) analysis was performed on those participants who had successfully completed the trial with good compliance rate. Results: With respect to primary outcomes, glycated hemoglobin decreased by 0.14 {\%} in the probiotics and increased by 0.02 {\%} in the placebo group in PP analysis (p <0.05, small effect size of 0.050), while these changes were not significant in ITT analysis. Fasting insulin increased by 1.8 µU/mL in placebo group and decreased by 2.9 µU/mL in probiotics group in PP analysis. These changes were significant between groups at both analyses (p <0.05, medium effect size of 0.062 in PP analysis and small effect size of 0.033 in ITT analysis). Secondary outcomes did not change significantly. Probiotics successfully passed through the gastrointestinal tract. Conclusion: Probiotics modestly improved HbA1c and fasting insulin in people with type 2 diabetes.",
keywords = "Blood pressure, Glycated hemoglobin, Glycemic control, High-sensitivity C-reactive protein, Homeostasis model assessment-estimated insulin resistance, Lipid profile, Probiotics, Type 2 diabetes mellitus",
author = "Somayyeh Firouzi and Majid, {Hazreen Abdul} and Amin Ismail and Kamaruddin, {Nor Azmi} and Barakatun-Nisak, {Mohd Yusof}",
year = "2016",
month = "3",
day = "17",
doi = "10.1007/s00394-016-1199-8",
language = "English",
pages = "1--16",
journal = "European Journal of Nutrition",
issn = "1436-6207",
publisher = "D. Steinkopff-Verlag",

}

TY - JOUR

T1 - Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes

T2 - a randomized controlled trial

AU - Firouzi, Somayyeh

AU - Majid, Hazreen Abdul

AU - Ismail, Amin

AU - Kamaruddin, Nor Azmi

AU - Barakatun-Nisak, Mohd Yusof

PY - 2016/3/17

Y1 - 2016/3/17

N2 - Aim: Evidence of a possible connection between gut microbiota and several physiological processes linked to type 2 diabetes is increasing. However, the effect of multi-strain probiotics in people with type 2 diabetes remains unclear. This study investigated the effect of multi-strain microbial cell preparation—also refers to multi-strain probiotics—on glycemic control and other diabetes-related outcomes in people with type 2 diabetes. Design: A randomized, double-blind, parallel-group, controlled clinical trial. Setting: Diabetes clinic of a teaching hospital in Kuala Lumpur, Malaysia. Participants: A total of 136 participants with type 2 diabetes, aged 30–70 years, were recruited and randomly assigned to receive either probiotics (n = 68) or placebo (n = 68) for 12 weeks. Outcomes: Primary outcomes were glycemic control-related parameters, and secondary outcomes were anthropomorphic variables, lipid profile, blood pressure and high-sensitivity C-reactive protein. The Lactobacillus and Bifidobacterium quantities were measured before and after intervention as an indicator of successful passage of the supplement through gastrointestinal tract. Statistical analysis: Intention-to-treat (ITT) analysis was performed on all participants, while per-protocol (PP) analysis was performed on those participants who had successfully completed the trial with good compliance rate. Results: With respect to primary outcomes, glycated hemoglobin decreased by 0.14 % in the probiotics and increased by 0.02 % in the placebo group in PP analysis (p <0.05, small effect size of 0.050), while these changes were not significant in ITT analysis. Fasting insulin increased by 1.8 µU/mL in placebo group and decreased by 2.9 µU/mL in probiotics group in PP analysis. These changes were significant between groups at both analyses (p <0.05, medium effect size of 0.062 in PP analysis and small effect size of 0.033 in ITT analysis). Secondary outcomes did not change significantly. Probiotics successfully passed through the gastrointestinal tract. Conclusion: Probiotics modestly improved HbA1c and fasting insulin in people with type 2 diabetes.

AB - Aim: Evidence of a possible connection between gut microbiota and several physiological processes linked to type 2 diabetes is increasing. However, the effect of multi-strain probiotics in people with type 2 diabetes remains unclear. This study investigated the effect of multi-strain microbial cell preparation—also refers to multi-strain probiotics—on glycemic control and other diabetes-related outcomes in people with type 2 diabetes. Design: A randomized, double-blind, parallel-group, controlled clinical trial. Setting: Diabetes clinic of a teaching hospital in Kuala Lumpur, Malaysia. Participants: A total of 136 participants with type 2 diabetes, aged 30–70 years, were recruited and randomly assigned to receive either probiotics (n = 68) or placebo (n = 68) for 12 weeks. Outcomes: Primary outcomes were glycemic control-related parameters, and secondary outcomes were anthropomorphic variables, lipid profile, blood pressure and high-sensitivity C-reactive protein. The Lactobacillus and Bifidobacterium quantities were measured before and after intervention as an indicator of successful passage of the supplement through gastrointestinal tract. Statistical analysis: Intention-to-treat (ITT) analysis was performed on all participants, while per-protocol (PP) analysis was performed on those participants who had successfully completed the trial with good compliance rate. Results: With respect to primary outcomes, glycated hemoglobin decreased by 0.14 % in the probiotics and increased by 0.02 % in the placebo group in PP analysis (p <0.05, small effect size of 0.050), while these changes were not significant in ITT analysis. Fasting insulin increased by 1.8 µU/mL in placebo group and decreased by 2.9 µU/mL in probiotics group in PP analysis. These changes were significant between groups at both analyses (p <0.05, medium effect size of 0.062 in PP analysis and small effect size of 0.033 in ITT analysis). Secondary outcomes did not change significantly. Probiotics successfully passed through the gastrointestinal tract. Conclusion: Probiotics modestly improved HbA1c and fasting insulin in people with type 2 diabetes.

KW - Blood pressure

KW - Glycated hemoglobin

KW - Glycemic control

KW - High-sensitivity C-reactive protein

KW - Homeostasis model assessment-estimated insulin resistance

KW - Lipid profile

KW - Probiotics

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84961197300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961197300&partnerID=8YFLogxK

U2 - 10.1007/s00394-016-1199-8

DO - 10.1007/s00394-016-1199-8

M3 - Article

C2 - 26988693

AN - SCOPUS:84961197300

SP - 1

EP - 16

JO - European Journal of Nutrition

JF - European Journal of Nutrition

SN - 1436-6207

ER -